Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman diseaseDavid C. Fajgenbaum, Thomas S. Uldrick|Journal of Clinical Investigation|2019Cited by 138
Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccinationSaishravan Shyamsundar, David C. Fajgenbaum, Caoilfhionn M Connolly et al.|Blood Neoplasia|2024Cited by 2